CD79A and respiratory tract infectious disorder: Clonal expansion of RBD-specific B‐cells and antibodies has been demonstrated and might also account for the quantitative increase of these antibodies as observed here [10]; however, one must be cautious because IgA and IgM assays might cross-react with non-SARS-CoV‐2 viral and bacterial agents causing respiratory infections [18].